Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19840311 | 1.00 | MEN1 (0.54) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL15561391 | 1.00 | MEN1 (0.54) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL16769871 | 0.93 | GPR183 (0.52) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL19840310 | 0.93 | DRD3 (0.50) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL16755567 | 0.93 | ACHE (0.48) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL15562263 | 0.93 | GPR183 (0.52) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL19840309 | 0.93 | ACHE (0.48) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL15562261 | 0.93 | GPR183 (0.52) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL16755523 | 0.93 | DRD3 (0.50) | MEN1KMT2ACYP1A2ACHEPKM | |
| SCHEMBL16755569 | 0.93 | ACHE (0.48) | MEN1KMT2ACYP1A2ACHEPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884825-B2 | Curcumin analogs and methods of making and using thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150152056-A1 | Curcumin Analogs and Methods of Making and Using Thereof | UNIVERSITY OF DELHI (IN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152056-A1 | Curcumin Analogs and Methods of Making and Using Thereof | COX15, HCCS, HMOX2 | MEN1 1508/4885KMT2A 2801/4885CYP1A2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.